score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545A	0.4378	201.0	0.0	0.0		Putatively Actionable	Pictilisib	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828							Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	1.0	0.0	0.0	PIK3CA p.E545A (Missense)	1.0	MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - High	FDA-Approved			Rearrangement	NTRK2	Fusion	NTRK2--ACOX2			0.0	0.0		Investigate Actionability - High	Entrectinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.	Rozlytrek [package insert]. San Francisco, CA: Genentech; 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf												0				NTRK2--ACOX2 Fusion		MO_1012		
Investigate Actionability - High	FDA-Approved			Rearrangement	FIP1L1	Fusion	FIP1L1--THG1L			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				FIP1L1--THG1L Fusion	0.0	MO_1012		
Investigate Actionability - High	FDA-Approved			Rearrangement	FIP1L1	Fusion	MUTYH--FIP1L1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				MUTYH--FIP1L1 Fusion	0.0	MO_1012		
Investigate Actionability - High	FDA-Approved			Rearrangement	NTRK3	Fusion	SAMD14--NTRK3			0.0	0.0		Investigate Actionability - High	Entrectinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.	Rozlytrek [package insert]. San Francisco, CA: Genentech; 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf												0				SAMD14--NTRK3 Fusion		MO_1012		
Investigate Actionability - High	FDA-Approved			Rearrangement	BCR	Fusion	RFX6--BCR			0.0	0.0		Investigate Actionability - High	Bosutinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.	Bosulif [package insert]. New York, NY: Pfizer Inc.; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf												0				RFX6--BCR Fusion	1.0	MO_1012		
Investigate Actionability - High	FDA-Approved			Rearrangement	ALK	Fusion	EMC1--ALK			0.0	0.0		Investigate Actionability - High	Alectinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.	Alecensa [package insert]. San Francisco, CA: Genentech; 2017.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf												0				EMC1--ALK Fusion	1.0	MO_1012		
Investigate Actionability - High	Guideline			Rearrangement	EML4	Fusion	KIF13A--EML4			0.0	0.0		Investigate Actionability - High	Crizotinib	Targeted therapy	ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf												0				KIF13A--EML4 Fusion	0.0	MO_1012		
Investigate Actionability - High	Guideline			Rearrangement	COL1A1	Fusion	CREBZF--COL1A1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf												0				CREBZF--COL1A1 Fusion	0.0	MO_1012		
Investigate Actionability - High	Guideline			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Nivolumab + ipilimumab	Immunotherapy	Nivolumab + ipilimumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf												0				 mutations per Mb		MO_1012		
Investigate Actionability - High	Clinical trial			Rearrangement	RET	Fusion	RET--DDX42			0.0	0.0		Investigate Actionability - High	Cabozantinib	Targeted therapy	Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated for efficacy in patients with RET fusion-positive tumors.	Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5.	https://doi.org/10.1158/2159-8290.CD-13-0035												0				RET--DDX42 Fusion	1.0	MO_1012		
Investigate Actionability - High	Preclinical			Rearrangement	SLC45A3	Fusion	FOSL1--SLC45A3			0.0	0.0		Investigate Actionability - High	Sorafenib	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166												0				FOSL1--SLC45A3 Fusion	1.0	MO_1012		
Investigate Actionability - High	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.R311W	0.1601	306.0	0.0	0.0		Investigate Actionability - High	Sunitinib	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability - High	Quizartinib	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	0.0	0.0	0.0	FLT3 p.R311W (Missense)	1.0	MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - High	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1851fs	0.1984	247.0	0.0	0.0		Investigate Actionability - High	Durvalumab	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z							Investigate Actionability - Low	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	0.0	0.0	0.0	ARID1A p.S1851fs (Frameshift)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MO_1012		
Investigate Actionability - Low	FDA-Approved			Rearrangement	PDGFRA	Fusion	PDGFRA--NTF4			0.0	0.0		Investigate Actionability - Low	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				PDGFRA--NTF4 Fusion	0.0	MO_1012		
Investigate Actionability - Low	FDA-Approved			Rearrangement	NTRK1	Fusion	NTRK1--RP11-566K19.5			0.0	0.0		Investigate Actionability - Low	Larotrectinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.	Vitrakvi [package insert]. Stamford, CT: Loxo Oncology, Inc.; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf												0				NTRK1--RP11-566K19.5 Fusion		MO_1012		
Investigate Actionability - Low	FDA-Approved			Rearrangement	NTRK1	Fusion	NTRK1--CHAF1B			0.0	0.0		Investigate Actionability - Low	Larotrectinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.	Vitrakvi [package insert]. Stamford, CT: Loxo Oncology, Inc.; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf												0				NTRK1--CHAF1B Fusion		MO_1012		
Investigate Actionability - Low	FDA-Approved			Rearrangement	PDGFRB	Fusion	HIC2--PDGFRB			0.0	0.0		Investigate Actionability - Low	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				HIC2--PDGFRB Fusion	0.0	MO_1012		
Investigate Actionability - Low	Clinical trial	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A392V	0.0503	159.0	0.0	0.0		Investigate Actionability - Low	Olaparib	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.A392V (Missense)	0.0	MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low	Clinical trial	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L3277P	0.2351	370.0	0.0	0.0		Investigate Actionability - Low	Olaparib	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.L3277P (Missense)	0.0	MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low	Clinical evidence			Somatic Variant	MSH2	Missense	p.T335P	0.2143	224.0	0.0	0.0		Investigate Actionability - Low	Pembrolizumab	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596												0	3.0	0.0	0.0	MSH2 p.T335P (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low	Clinical evidence			Somatic Variant	FLCN	Deletion	p.330_331SS>S	0.3973	73.0	0.0	0.0		Investigate Actionability - Low	Everolimus	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344												0	0.0	0.0	0.0	FLCN p.330_331SS>S (Deletion)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low	Preclinical			Rearrangement	RUNX1T1	Fusion	RUNX1T1--SRMS			0.0	0.0		Investigate Actionability - Low	Panobinostat + Azacitidine	Targeted therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf												0				RUNX1T1--SRMS Fusion		MO_1012		
Investigate Actionability - Low	Preclinical			Rearrangement	RUNX1T1	Fusion	C8orf34--RUNX1T1			0.0	0.0		Investigate Actionability - Low	Panobinostat + Azacitidine	Targeted therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf												0				C8orf34--RUNX1T1 Fusion		MO_1012		
Investigate Actionability - Low	Preclinical			Rearrangement	BRD4	Fusion	DMBT1--BRD4			0.0	0.0		Investigate Actionability - Low	JQ1	Targeted therapy	BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.	Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73.	https://doi.org/10.1038/nature09504												0				DMBT1--BRD4 Fusion	0.0	MO_1012		
Investigate Actionability - Low	Preclinical		Clinical evidence	Rearrangement	ERG	Fusion	MIR145--ERG			0.0	0.0		Investigate Actionability - Low	Rucaparib	Targeted therapy	Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.	Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.	https://doi.org/10.1371/journal.pone.0060408							Investigate Actionability - Low	0.0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.	https://doi.org/10.1038/sj.onc.1210237	0				MIR145--ERG Fusion	0.0	MO_1012		
Investigate Actionability - Low	Inferential			Rearrangement	CCND3	Fusion	CCND3--CDKN1A			0.0	0.0		Investigate Actionability - Low	Palbociclib	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(6;14) resulting in CCND3 overexpression.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122												0				CCND3--CDKN1A Fusion	1.0	MO_1012		
Investigate Actionability - Low	Inferential		Clinical evidence	Rearrangement	CCND1	Fusion	CCND1--PPP1R13L			0.0	0.0		Investigate Actionability - Low	Palbociclib	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122							Investigate Actionability - Low	0.0	In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.	Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5.	https://doi.org/10.1038/ng.2583	0				CCND1--PPP1R13L Fusion	1.0	MO_1012		
Investigate Actionability - Low	Inferential		Clinical evidence	Rearrangement	CCND1	Fusion	CCND1--MYLK			0.0	0.0		Investigate Actionability - Low	Palbociclib	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122							Investigate Actionability - Low	0.0	In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.	Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5.	https://doi.org/10.1038/ng.2583	0				CCND1--MYLK Fusion	1.0	MO_1012		
Investigate Actionability - Low	Inferential		Inferential	Somatic Variant	RAD51D	Missense	p.R266C	0.3788	66.0	0.000198	0.0		Investigate Actionability - Low	Platinum	Chemotherapy	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287							Investigate Actionability - Low	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	0.0	0.0	0.0	RAD51D p.R266C (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low		Clinical evidence		Somatic Variant	ESR1	Frameshift	p.T585fs	0.1333	75.0	0.0	0.0								Investigate Actionability - Low	Tamoxifen + Letrozole	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823						0	0.0	0.0	0.0	ESR1 p.T585fs (Frameshift)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Investigate Actionability - Low			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.4561	114.0	0.0	0.0														Investigate Actionability - Low	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0	11.0	0.3636	0.8098	CTNNB1 p.T41A (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Rearrangement	ARID1A	Fusion	SDC3--ARID1A			0.0	0.0																			0				SDC3--ARID1A Fusion		MO_1012		
Biologically Relevant				Rearrangement	PIK3CA	Fusion	PTCD3--PIK3CA			0.0	0.0																			0				PTCD3--PIK3CA Fusion		MO_1012		
Biologically Relevant				Rearrangement	FLCN	Fusion	AZI1--FLCN			0.0	0.0																			0				AZI1--FLCN Fusion		MO_1012		
Biologically Relevant				Rearrangement	IL12RB1	Fusion	RP11-147N17.1--IL12RB1			0.0	0.0																			0				RP11-147N17.1--IL12RB1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	CCNE1	Fusion	BCL6B--CCNE1			0.0	0.0																			0				BCL6B--CCNE1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	SMARCA4	Fusion	SMARCA4--KIF7			0.0	0.0																			0				SMARCA4--KIF7 Fusion		MO_1012		
Biologically Relevant				Rearrangement	SF3B1	Fusion	SF3B1--SIX4			0.0	0.0																			0				SF3B1--SIX4 Fusion		MO_1012		
Biologically Relevant				Rearrangement	PRPF8	Fusion	PRPF8--GMEB2			0.0	0.0																			0				PRPF8--GMEB2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	MAP2K2	Fusion	MAP2K2--BRPF3			0.0	0.0																			0				MAP2K2--BRPF3 Fusion		MO_1012		
Biologically Relevant				Rearrangement	JAK3	Fusion	JAK3--ODF3L2			0.0	0.0																			0				JAK3--ODF3L2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	JAK3	Fusion	JAK3--ADAMTS9-AS2			0.0	0.0																			0				JAK3--ADAMTS9-AS2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	IDH2	Fusion	IDH2--WISP2			0.0	0.0																			0				IDH2--WISP2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	DNMT3A	Fusion	DNMT3A--MAG			0.0	0.0																			0				DNMT3A--MAG Fusion		MO_1012		
Biologically Relevant				Rearrangement	DNMT3A	Fusion	SNRNP48--DNMT3A			0.0	0.0																			0				SNRNP48--DNMT3A Fusion		MO_1012		
Biologically Relevant				Rearrangement	DNMT3A	Fusion	GNS--DNMT3A			0.0	0.0																			0				GNS--DNMT3A Fusion		MO_1012		
Biologically Relevant				Rearrangement	CDKN2B	Fusion	CDKN2B--SCRT1			0.0	0.0																			0				CDKN2B--SCRT1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	BCOR	Fusion	BCOR--TMEM53			0.0	0.0																			0				BCOR--TMEM53 Fusion		MO_1012		
Biologically Relevant				Rearrangement	BCOR	Fusion	FLT4--BCOR			0.0	0.0																			0				FLT4--BCOR Fusion		MO_1012		
Biologically Relevant				Rearrangement	AKT2	Fusion	AKT2--VPS51			0.0	0.0																			0				AKT2--VPS51 Fusion		MO_1012		
Biologically Relevant				Rearrangement	AKT2	Fusion	SUMO2--AKT2			0.0	0.0																			0				SUMO2--AKT2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	AKT2	Fusion	ABLIM1--AKT2			0.0	0.0																			0				ABLIM1--AKT2 Fusion		MO_1012		
Biologically Relevant				Rearrangement	AKT1	Fusion	AKT1--OR52J2P			0.0	0.0																			0				AKT1--OR52J2P Fusion		MO_1012		
Biologically Relevant				Rearrangement	AKT1	Fusion	C17orf53--AKT1			0.0	0.0																			0				C17orf53--AKT1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	EGFR	Fusion	TSSC2--EGFR			0.0	0.0																			0				TSSC2--EGFR Fusion		MO_1012		
Biologically Relevant				Rearrangement	MAP2K1	Fusion	TMEM130--MAP2K1			0.0	0.0																			0				TMEM130--MAP2K1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	GATA3	Fusion	TEX19--GATA3			0.0	0.0																			0				TEX19--GATA3 Fusion		MO_1012		
Biologically Relevant				Rearrangement	CDK4	Fusion	SH3TC1--CDK4			0.0	0.0																			0				SH3TC1--CDK4 Fusion		MO_1012		
Biologically Relevant				Rearrangement	TSC1	Fusion	PRDX6--TSC1			0.0	0.0																			0				PRDX6--TSC1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	POLE	Fusion	FRMD6--POLE			0.0	0.0																			0				FRMD6--POLE Fusion		MO_1012		
Biologically Relevant				Rearrangement	POLD1	Fusion	ELP4--POLD1			0.0	0.0																			0				ELP4--POLD1 Fusion		MO_1012		
Biologically Relevant				Rearrangement	TSC2	Fusion	CYP2D8P1--TSC2			0.0	0.0																			0				CYP2D8P1--TSC2 Fusion		MO_1012		
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R2134Q	0.511	272.0	1.6e-05	0.0																			0	0.0	0.0	0.0	MTOR p.R2134Q (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	RAF1	Missense	p.N71D	0.3582	134.0	0.0	0.0																			0	2.0	0.5	0.0	RAF1 p.N71D (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A203T	0.47100000000000003	293.0	0.0	0.0																			0	4.0	0.25	0.0504	RUNX1T1 p.A203T (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R467*	0.4054	37.0	0.0	0.0																			0	3.0	0.0	0.0	RB1 p.R467* (Nonsense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V742fs	0.3097	113.0	0.0	0.0																			0	0.0	0.0	0.0	RB1 p.V742fs (Frameshift)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.T676fs	0.3641	206.0	0.0	0.0																			0	0.0	0.0	0.0	NF1 p.T676fs (Frameshift)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	NF1	Missense	p.T1881S	0.018000000000000002	334.0	0.0	0.0																			0	0.0	0.0	0.0	NF1 p.T1881S (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.A95V	0.54	50.0	0.0	0.0																			0	1.0	0.0	0.0	KEAP1 p.A95V (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.P10S	0.1304	46.0	0.0	0.0																			0	1.0	0.0	0.0	IL12RB1 p.P10S (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.R95Q	0.2121	198.0	0.0	0.0																			0	1.0	0.0	0.0	CCNE1 p.R95Q (Missense)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Somatic Variant	ERG	Frameshift	p.P411fs	0.3992	238.0	0.0	0.0																			0	0.0	0.0	0.0	ERG p.P411fs (Frameshift)		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	MO_1012-Normal
Biologically Relevant				Copy Number	MLH1	Deletion				0.0	0.0																			0				MLH1 Deletion		MO_1012	MO_1012-Tumor-Subcutaneous_nodule	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2--LY9 Fusion, RNF43 p.G659fs (Frameshift), MUC16--RNF43 Fusion, MLH1 Deletion, FRMD6--POLE Fusion, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2--LY9 Fusion, RNF43 p.G659fs (Frameshift), MUC16--RNF43 Fusion, MLH1 Deletion, FRMD6--POLE Fusion, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MO_1012		
Biologically Relevant				Mutational Signature	COSMIC Signature 6		0.543																							0				COSMIC Signature 6 (54%)		MO_1012		
Biologically Relevant				Mutational Signature	COSMIC Signature 15		0.242																							0				COSMIC Signature 15 (24%)		MO_1012		
